FBIOP Dividend History & Description — Fortress Biotech Inc
Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. Co.'s product candidates include: MB-107 (XSCID), an ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency; Intravenous Tramadol, for the treatment of moderate to moderately severe post-operative pain; and CUTX-101, a copper histidinate injection for the treatment of Menkes disease. Co.'s other product candidates include: ConVax, CEVA-101, CEVA-D and CEVA-102, TAMID-001, AVTS-001, CNDO-109 and Methazalomide. When considering the Fortress Biotech Inc stock dividend history, we have taken known splits into account, such that the FBIOP dividend history is presented on a split-adjusted ("apples to apples") basis. Fortress Biotech Inc dividend history is presented both in graphical/chart form, and as a FBIOP dividend history data table along the right-hand column.